Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials
Open Access
- 1 July 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (7), ofaa248
- https://doi.org/10.1093/ofid/ofaa248
Abstract
Background. Renal impairment is not a consistently cited risk factor for recurrent Clostridioides difficile infection (rCDI). We examined the association between renal impairment and rCDI and the effect of bezlotoxumab, an anti-toxin B monoclonal antibody, in reducing rCDI in participants with renal impairment. Methods. We pooled data from 2 randomized, double-blind, placebo-controlled, multicenter, phase 3 clinical trials conducted in participants receiving bezlotoxumab or placebo infusion during oral antibacterial drug treatment for CDI. We assessed the association between renal impairment and rCDI in placebo-treated participants and evaluated the effect of bezlotoxumab vs placebo in reducing rCDI among participants with renal impairment, defined as an estimated glomerular filtration rate <90 mL/min. Results. The proportion of placebo-treated participants experiencing rCDI within 12 weeks was higher in those with renal impairment (n = 919) vs those without renal impairment (n = 612; 36.6% and 27.7%, respectively; difference, 8.9%; 95% CI, 1.3% to 16.3%). Renal impairment was significantly associated with a higher rate of recurrence in placebo-treated participants lacking commonly recognized risk factors for rCDI (renal impairment as only risk factor, 28.8%; vs normal renal function and no risk factors, 12.5%; difference, 16.3%; 95% CI, 3.4% to 28.8%). Among all participants with renal impairment, the rate of rCDI was 19.5% among bezlotoxumab-treated vs 36.6% among placebo-treated participants (difference, -17.1%; 95% CI, -23.4% to -10.6%). Conclusions. This post hoc analysis adds to the literature suggesting an association of renal impairment as an independent risk factor for rCDI and provides preliminary evidence that patients with renal impairment who suffer with CDI may benefit from adjunctive treatment with bezlotoxumab.Funding Information
- Merck Sharp & Dohme Corp
- Merck & Co., Inc.
This publication has 31 references indexed in Scilit:
- Multistate Point-Prevalence Survey of Health Care–Associated InfectionsThe New England Journal of Medicine, 2014
- Renal Impairment and Clinical Outcomes of Clostridium difficile Infection in Two Randomized TrialsAmerican Journal of Nephrology, 2013
- Epidemiology, diagnosis and treatment ofClostridium difficileinfectionExpert Review of Anti-infective Therapy, 2012
- Clostridium difficile Infection in Patients With Chronic Kidney DiseaseMayo Clinic Proceedings, 2012
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trialThe Lancet Infectious Diseases, 2012
- Risk Factors Associated With Complications and Mortality in Patients With Clostridium difficile InfectionClinical Infectious Diseases, 2011
- Fidaxomicin versus Vancomycin forClostridium difficileInfectionThe New England Journal of Medicine, 2011
- Clostridium difficile infection in Europe: a hospital-based surveyThe Lancet, 2011
- Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration RateAnnals of Internal Medicine, 2006
- Comparative analysis of two ratesStatistics in Medicine, 1985